Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
November 13, 2018First oral Rapid-Acting Antidepressant to be granted Breakthrough Designation
WILMINGTON, Del. - NeuroRx, a clinical stage biopharma company focused on the development of Rapid Acting Antidepressants (RAADs) that target the brain’s NMDA receptor, has been granted...
-
September 5, 2018
WILMINGTON, Del., Sept. 05, 2018 -- NeuroRx, a clinical stage biopharma company developing NRX-101, the first oral therapy for Severe Bipolar Depression with Acute Suicidal Ideation & Behavior...
-
September 4, 2018
WILMINGTON, De. , Sept. 04, 2018 -- NeuroRx, a clinical stage biopharma company developing NRX-101, the first oral therapy for Severe Bipolar Depression with Acute Suicidal Ideation & Behavior...
-
June 11, 2018
WILMINGTON, Del. - NeuroRx, Inc., a clinical stage biopharma company has completed the feasibility enrollment phase of its 2b/3 clinical trial of NRX-101 for the treatment of suicidal bipolar...
-
May 7, 2018FDA deems proposed Phase 2b/3 trial adequate to support a regulatory submission
WILMINGTON, Del., May 07, 2018 -- NeuroRx, a clinical stage biopharmaceutical company developing the first drug regimen to treat Severe Bipolar Depression in patients with Acute Suicidal Ideation...
Click here to view our corporate presentation or on the image below
![]() |